Corcept Therapeutics

Associate Director, IT Business Relationship Management (Compliance)

Redwood City, California, United States

Auto‑apply with AI Apply

$60,000 – $90,000Compensation

Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, Healthcare, IT, ComplianceIndustries

Requirements

Candidates should possess a Bachelor’s degree in a relevant field, along with a minimum of 7 years of experience in IT Business Relationship Management, preferably within a highly regulated industry. Strong communication and interpersonal skills are essential, as is the ability to translate complex business needs into technical requirements. Experience working with compliance teams and understanding regulatory frameworks is highly desirable.

Responsibilities

The Associate Director, IT Business Relationship Management (Compliance) will partner with the Compliance organization to deliver IT solutions aligned with regulatory requirements and business strategy, translating business needs into scalable and compliant processes and technical solutions. They will oversee end-to-end IT project management, including planning, design, and implementation, ensuring projects meet timelines and business impact. Furthermore, this role will develop and maintain a technology roadmap for the Compliance organization, tracking and managing the TCO of related technologies while supporting strategic business objectives and evolving regulatory landscapes.

Skills

IT Business Relationship Management

Compliance

Regulatory Frameworks

Project Management

IT Project Management

Communication Skills

Interpersonal Skills

Requirements Translation

Technology Roadmap

TCO Management

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Key Metrics

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free